
# Namibia ALMA Quarterly Report Quarter Four, 2022




## **Scorecard for Accountability and Action**



Commodities Financed		
IRS financing 2022 (% of at-risk population)		60
Public sector RDT financing 2022 projection (% of need)		100
Public sector ACT financing 2022 projection (% of need)		100
Policy		
Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan	Γ	
Malaria activities targeting IDPs in Malaria Strategic Plan	Ī	
Country Reporting Launch of Zero Malaria Starts with Me Campaign		
Resistance Monitoring, Implementation and Impact		
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		2
Insecticide resistance monitored since 2015 and data reported to WHO		
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)	•	
ACTs in stock (>6 months stock)	•	
LLIN/IRS campaign on track		
IRS Operational Coverage (%)		23
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs an	d C	ovid 19
Scale of Implementation of iCCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)		0
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021)		81
Vitamin A Coverage 2021 (2 doses)		59
DPT3 coverage 2021 (vaccination among 0-11 month olds)		93
% Population Fully Vaccinated Against COVID-19		19
5 m 5-0 5m		

Malaria transmission is confined to the north-east part of Namibia where malaria is endemic and about 72% of the population of the country is at risk. The annual reported number of malaria cases in 2021 was 13,738 with 14 deaths.

## Key



## Namibia ALMA Quarterly Report Quarter Four, 2022



### Malaria

#### **Global Fund Update**

The Global Fund has announced that Namibia will receive U\$\$32.8 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Namibia's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For Namibia this is calculated at U\$\$3.1 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Namibia is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

#### **Progress**

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, Namibia secured sufficient funding for the required number of ACTs and RDTs for 2022 and has sufficient stocks of RDTs. The country has reported the insecticide resistance data to WHO. Namibia has recently launched the Zero Malaria Starts with Me campaign.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Namibia has enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Elimination Scorecard, however this is not yet shared to the ALMA Scorecard Hub. The country has established End Malaria Councils at sub-national level.

#### **Impact**

The annual reported number of malaria cases in 2021 was 13,738 with 14 deaths.

#### **Key Challenges**

- Maintaining malaria high on the political and funding agenda.
- There is a need to strengthen cross border collaboration with neighbouring countries.
- Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and Neglected Tropical Diseases.

#### **Previous Key Recommended Action**

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic	Q4 2022		Namibia has sufficient insecticides for the IRS campaign for 2022/2023. The country also has sufficient stocks of RDTs. Stock outs were experienced at the Health Facility level due to poor stock management. The planned 2022/2023 IRS campaign commenced in September 2022, with the training of field teams, community sensitization and the launching of the campaign

Namibia has responded positively to the recommended action on addressing the lack of data on iCCM and continues to strengthen access to treatment of malaria, pneumonia

**New Key Recommended Action** 

Objective	Action Item	Suggested completion timeframe
Impact	Investigate and address the reasons for the increase in estimated malaria incidence and mortality between 2015 and 2021	Q4 2023

### **RMNCAH and NTDs**

### **Progress**

Namibia has recently increased coverage of ARTs in children 0-14 and has good coverage of DPT3. The country has enhanced tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in Namibia is shown using a composite index calculated from preventive chemotherapy coverage achieved for schistosomiasis and soil transmitted helminths. In 2021, preventive chemotherapy coverage in Namibia was 0% for the two diseases. Overall, the NTD preventive chemotherapy coverage index for Namibia in 2021 is 0, with no change compared with the 2020 index value of 0.

**Previous Key Recommended Actions** 

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
RMNCAH <sup>1</sup> : Impact	Ensure that essential RMNCAH services are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic. Address any stockouts of essential RMNCAH commodities	Q4 2022		WHO guidelines for continuity of essential services are currently being reviewed and revised in the context of the current circumstances relating to the pandemic. These are expected to be completed at the end of the financial year.
NTDs	Ensure that NTD interventions including Mass Drug Administration, vector control and Morbidity Management and Disability Prevention are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic. This includes prioritising key necessary catch-up activities	Q4 2022		The country is conducting only NTD routine activities including NTD case management at health facility level whilst respecting COVID-19 preventive measures. Since 2020, the country has not organized MDA due to the WHO recommendation to wait for the taeniasis prevalence survey. The country is waiting for WHO support

**New Key Recommended Action** 

Objective	Action Item	Suggested completion timeframe
NTDs	Recognising the negative impact of COVID-19 on the 2021 MDA coverage, ensure that NTD interventions including MDA for schistosomiasis and soil transmitted helminths are implemented	Q4 2023

<sup>&</sup>lt;sup>1</sup> RMNCAH metrics, recommended actions and response tracked through WHO

